Bora-Pharmaceuticals-Header Bora-Pharmaceuticals-Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Lead Product(s): 010DS-Zn

            Therapeutic Area: Oncology Product Name: 010DS-Zn

            Highest Development Status: Undisclosed Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 22, 2021

            Details:

            Xylonix demonstrated that its drug compound 010DS-Zn markedly reduced M2 population, while simultaneously boosting anti-cancer CD4 and CD8 T cells.